Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Unspecified Adult Solid Tumor, Protocol Specific: early-phase trial registry
5 of 112 indexed Unspecified Adult Solid Tumor, Protocol Specific trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #115 of 28,707 conditions by registered trial count.
112 US clinical trials · 5 currently recruiting · #115 of 28,707 conditions by registered trial count
Unspecified Adult Solid Tumor, Protocol Specific: 112 US clinical trials tracked, 5 recruiting.
Unspecified Adult Solid Tumor, Protocol Specific is the subject of 112 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 93 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 26 of these trials.
Enrollment posture brief
Registry condition unspecified-adult-solid-tumor-protocol-specific
OPEN 5 | RECR 4% | LATE 10 | EARLY 93 | RANK #115 | SPON 26
Volume-matched condition peers
Nearest open-share peer: Attention Deficit Disorder With Hyperactivity (5% recruiting · 21 trials)
Unspecified Adult Solid Tumor, Protocol Specific lists 5 open slots (4% of 112 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Unspecified Adult Solid Tumor, Protocol Specific on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Unspecified Adult Solid Tumor, Protocol Specific is recruiting below its size-band peers.
5 of 112 indexed trials (4.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Unspecified Adult Solid Tumor, Protocol Specific research.
National Cancer Institute (NCI) accounts for 26 of 112 trials (23.2%). 46 distinct sponsors appear on at least one study for this condition label.
-
Most Unspecified Adult Solid Tumor, Protocol Specific trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 84 trials that report a genuine target (sentinel values excluded). 66 of those (78.6%) plan for fewer than 100 participants.
-
Unspecified Adult Solid Tumor, Protocol Specific research is mostly interventional.
107 interventional and 5 observational studies make up this index (95.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
112 total, page 2 of 3
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Mayo Clinic
NCT00949949
Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
University of Texas Southwestern Medical Center
NCT00855803
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
NCT00253344
Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00368914
Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00423865
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
University of California, Davis
NCT00389584
Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
University of Nebraska
NCT01206465
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Pfizer
NCT01337765
O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors
Case Comprehensive Cancer Center
NCT00002604
BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00022529
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Northwestern University
NCT01898130
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT01191216
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
City of Hope Medical Center
NCT00825201
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Edward Kim
NCT01924260
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Roswell Park Cancer Institute
NCT01497392
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
University of Pittsburgh
NCT00008125
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
NCT00544284
Perillyl Alcohol in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
NCT00002862
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
Yale University
NCT00002950
Decitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00030615
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
Roswell Park Cancer Institute
NCT00003294
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT00079352
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
Georgetown University
NCT00003125
3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors
Fox Chase Cancer Center
NCT01470365
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT00112476
ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
National Institutes of Health Clinical Center (CC)
NCT00387608
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
NCT00006465
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
California Cancer Consortium
NCT00387504
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
University of Chicago
NCT00002939
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
Eisai
NCT01418677
Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors
Roswell Park Cancer Institute
NCT00238225
Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors
University of Southern California
NCT01957995
SU6668 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00024206
BMS-599626 in Treating Patients With Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
NCT00093730
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT00002759
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
NYU Langone Health
NCT00004002
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
University of Kansas
NCT00100958
Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy
University of Rochester
NCT00005994
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
NCT00021164
BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00043095
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Vion Pharmaceuticals
NCT00016874
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
NCT00020371
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
NCT00019656
UCN-01 in Treating Patients With Advanced Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00003289
SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors
Ohio State University Comprehensive Cancer Center
NCT00006000
Perifosine in Treating Patients With Advanced Solid Tumors
University of Wisconsin, Madison
NCT00005794
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
NCT00014261
Vaccine Therapy in Treating Patients With Advanced Cancer
Jonsson Comprehensive Cancer Center
NCT00004881
PS-341 in Treating Patients With Advanced Cancer
Mayo Clinic
NCT00006362
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00004059
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 85 |
| Phase 2 | 8 |
| Phase 3 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Unspecified Adult Solid Tumor, Protocol Specific records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Unspecified Adult Solid Tumor, Protocol Specific trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Unspecified Adult Solid Tumor, Protocol Specific page
112 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Unspecified Adult Solid Tumor, Protocol Specific trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Unspecified Adult Solid Tumor, Protocol Specific trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Unspecified Adult Solid Tumor, Protocol Specific condition card totals 112 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.